Small-cap stocks have made a triumphant return to the limelight. After lagging behind their larger counterparts for an extended period, these small-cap equities are now charging ahead as investors redirect their focus towards this sector once again.

The small-cap Russell 2000 index has surged by 10% in July, outperforming the S&P 500 which showed a flat performance, and overshadowing the tech-heavy Nasdaq 100 that experienced a nearly 5% decline. This shift was inevitable, a tectonic movement that had been brewing beneath the surface for some time.

For years, tech stocks reigned supreme fueled by the mania surrounding artificial intelligence. However, as the market anticipated upcoming interest rate cuts this September, the unsustainable hyper-growth of the sector became increasingly apparent.

Conversely, small-cap stocks bore the brunt of the Federal Reserve’s monetary policies. Restricted by their size, these companies lacked the abundant access to capital enjoyed by larger enterprises, resulting in more expensive debt borrowing. The constrained growth of small-cap stocks in the past years was a direct consequence of these limitations.

The S&P 500 had outperformed the Russell 2000 by over 50%, while the Nasdaq 100 had more than doubled the small-cap index’s performance. Now, the tide has turned, shining a spotlight on three exceptional small-cap stocks that demand investor attention.

Starring on the stage is clinical-stage biotech company Longeveron (NASDAQ:LGVN), dedicated to combating age-related and life-threatening conditions. Its flagship investigational drug Lomecel-B, currently undergoing Phase 2b trials, aims to address a broad spectrum of diseases with a focus on treating the rare pediatric congenital heart birth defect known as hypoplastic left heart syndrome (HLHS).

Following a successful investigator meeting discussing the drug’s progress and the operational implementation of clinical trials, Longeveron’s stock witnessed a threefold increase in value. Despite relinquishing a substantial portion of those gains, the stock remains down by 75% year-to-date, presenting a compelling case for the continued advancement of Lomecel-B.

In a recent development, the therapy secured a regenerative medicine advanced therapy (RMAT) designation for its efficacy in treating Alzheimer’s patients. Lomecel-B exhibited promise by either slowing down or preventing the disease’s progression compared to a placebo. The RMAT label was designed to expedite the development and evaluation of regenerative medicine treatments.

Capitaizing on its soaring stock value, Longeveron capitalized on this momentum to boost its financial standing through stock sales. With shares currently sitting approximately 300% above recent lows, the company may opt for a similar strategy to further fortify its balance sheet.

Once a pioneering networking equipment giant, Netgear (NASDAQ:NTGR) now navigates a more challenging path. Over the past five years, the stock has witnessed a sharp decline of 53% in its value, significantly underperforming the Russell 2000 across various timeframes.

The Rise of Netgear and Solid Power Stocks: Market Transformations Unveiled

Netgear’s Ascension

Netgear’s stock has doubled in value, painting a promising picture in the tumultuous waters of the market. However, recent setbacks saw it lose 20%.

The winds of Wall Street have changed direction, now whispering favorable sentiments towards Netgear. Analysts at Raymond James have started heralding the company, claiming it was abandoned by investors and analysts alike.

See also  Ford's Rough Ride: A Bumpy Road Ahead

Windward Management, the hedge fund, has taken a notable 4% stake in Netgear, placing its bets on a brighter future for the networking equipment manufacturer. The fund believes Netgear has weathered the worst and is sailing towards calmer waters, remaining profitable on an EBITDA basis for the past two decades. Moreover, shares are trading at a discount, almost mirroring the cash reserves of the company during the same period.

Marked as close to zero value by the market, Netgear is poised to soar as fresh management sweeps its inventory clean, while the Netgear for Business segment stands robust. The stock has soared by 36% since early May, and with Windward’s call for a substantial stock buyback program, the shares might elevate even higher.

The Power Play by Solid Power (SLDP)

Source: T. Schneider / Shutterstock.com

Dynamic yet unproven, Solid Power (NASDAQ:SLDP) is on a fast track with its advanced cell designs in the realm of solid-state battery production. Though a risky venture as a small-cap stock, its long-term payoff potential is enormous.

Key to Solid Power’s allure is the robust automotive endorsements it has garnered. Industry majors such as Ford (NYSE:F) and BMW (OTCMKTS:BMWYY) stand in its corner. Furthermore, a strategic alliance with SK On, the South Korean counterpart of

Exploring the Growth Trajectory of Solid State Battery Maker

Solid Power, through its licensing of SLDP’s design and technology, recently had a manufacturing line installed by SK On, marking a significant milestone in its journey. The company is pushing forward, aiming to deliver its innovative A-2 cell prototype for testing to partners. As Solid Power surpasses key milestones, it reaps the fruits of its labor in the form of payments from collaborators.

Financial Progress in the First Quarter

The primary quarter unveiled a noteworthy increase in payments, surging by $2.2 million to reach $6 million. While this figure may seem modest, it acts as a compass pointing towards Solid Power’s promising trajectory. Trading at less than $2 per share, the solid-state battery innovator presents a volatile outlook for investors. Thus, a cautious approach is advisable rather than a wholehearted plunge into this small-cap stock.

Investment Outlook

For individuals considering their investment portfolios, Solid Power warrants attention as a potentially lucrative addition for the speculative segment. Amidst the tumultuous landscape of solid-state battery makers, this company stands out as a prospective contender worth exploring further.

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace avoids delving into companies with market caps below $100 million or those trading less than 100,000 shares daily. These “penny stocks” often serve as breeding grounds for fraudulent activities and market manipulations. In the case where we cover low-volume stocks, we mandate disclosure by our writers and provide necessary warnings to our readers.

Enhance Knowledge: Dig Deeper into Penny Stocks — How to Navigate the Terrain Safely

The author, Rich Duprey, with two decades of experience in stock and investment analysis, has shared insights in prestigious platforms like Nasdaq.com, The Motley Fool, and Yahoo! Finance. His expertise has been sought after by top financial publications, bringing a wealth of knowledge to the investing community.